翰森制药(03692)拟折让约6.49%配股 净筹约38.97亿港元

Group 1 - The company, Hansoh Pharmaceutical (03692), has entered into a placement agreement to issue 108 million shares at a price of HKD 36.30 per share, representing approximately 1.78% of the enlarged issued share capital post-placement [1] - The placement price of HKD 36.30 is approximately 6.49% lower than the closing price of HKD 38.82 on August 19, 2025 [1] Group 2 - The net proceeds from the placement, after deducting commissions, fees, and transaction costs, are estimated to be approximately HKD 3.897 billion, with a net price per share of about HKD 36.08 [2] - The company plans to allocate approximately 65% of the net proceeds for the research and development of new innovative drugs in areas such as oncology, autoimmune diseases, central nervous system, and metabolic diseases, as well as licensing innovative drugs and technology platforms [2] - Approximately 25% of the proceeds will be used for constructing new innovative drug production facilities and R&D laboratories, and upgrading existing R&D laboratories and production facilities [2] - The remaining 10% will be allocated for working capital and other general corporate purposes [2]